Bactiguard donates money to research on COVID-19
To contribute to the research on COVID-19, Bactiguard donates SEK 120,000 to Karolinska Institutet (KI) at Danderyd Hospital.
"We have collaborated with Karolinska Institutet at Danderyd Hospital (KI DS) since 2010, where we share lab resources to be able to test how Bactiguard's coating technology interacts with blood. In addition, Bactiguard has actively engaged in the fight against COVID-19 and being able to contribute further was natural to us,” says Stefan Grass, Chief Medical Officer.
The donation will be used to further equip a lab at Karolinska Institutet at Danderyd Hospital, so that it facilitates research on COVID-19. The research is conducted by, among others, the researcher Charlotte Thålin at Danderyd Hospital AB, in collaboration with Karolinska Institutet and the Royal Institute of Technology (KTH), and aims to develop and evaluate a test for COVID-19, but also involves basic research on SARS-CoV-2 and COVID-19.
“Thanks to the donation from Bactiguard, we have the opportunity to increase the speed of the project. The project will give us valuable knowledge about COVID-19 and diagnosis of the disease,” says Professor Håkan Wallén, at Karolinska Institutet at Danderyd Hospital.
"For a Swedish company like Bactiguard with research, development and production in Sweden, it is extremely valuable and rewarding to have a close and good collaboration with the healthcare sector and academia in Sweden," continues Stefan Grass, who is supported by Håkan Wallén: "We appreciate the collaboration with Bactiguard, it shows the strength of the interaction between academia and industry”.
For further information, please contact:
Stefan Grass, Chief Medical Officer, mobile: 0707-25 24 48
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.
Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.
Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives at www.bactiguard.com
Tags:
